TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dance on Patients With Fibromyalgia
Brief Summary: The aim of the present study is to assess the effectiveness of belly dance as a treatment for pain and improving the quality of life of patients with fibromyalgia.

Eighty female patients with fibromyalgia between 18 to 65 years were randomly allocated to a dance group (n=40) and control group (n=40). Patients in the dance group underwent 16 weeks of belly dance twice a week, while the patients in the control group remained on a waiting list. Patients were evaluated with regard to pain (Visual Analogue Scale), function (6 minute walk test), quality of life (Fibromyalgia Impact Questionnaire and SF-36), depression (Beck Inventory), anxiety (State-Trait Anxiety Inventory) and self-image (Body Dysmorphic Disorder Examination) questionnaire. Evaluations were carried out at baseline, after 16 weeks and after 32 weeks.


Options:
A: Arm Label: Strength training; Type: EXPERIMENTAL; Interventions: Behavioral: Strength training | Arm Label: Aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): Strength training | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise
B: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education
C: Arm Label: Dance Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dance | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: Other: Control Group | Intervention Type: BEHAVIORAL; Name: Dance; Assigned to Arm(s): Dance Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
D: Arm Label: CFQ Qigong training group; Type: ACTIVE_COMPARATOR; Interventions: Other: CFQ Qigong | Intervention Type: OTHER; Name: CFQ Qigong; Assigned to Arm(s): CFQ Qigong training group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dance on Patients With Fibromyalgia
Brief Summary: The aim of the present study is to assess the effectiveness of belly dance as a treatment for pain and improving the quality of life of patients with fibromyalgia.

Eighty female patients with fibromyalgia between 18 to 65 years were randomly allocated to a dance group (n=40) and control group (n=40). Patients in the dance group underwent 16 weeks of belly dance twice a week, while the patients in the control group remained on a waiting list. Patients were evaluated with regard to pain (Visual Analogue Scale), function (6 minute walk test), quality of life (Fibromyalgia Impact Questionnaire and SF-36), depression (Beck Inventory), anxiety (State-Trait Anxiety Inventory) and self-image (Body Dysmorphic Disorder Examination) questionnaire. Evaluations were carried out at baseline, after 16 weeks and after 32 weeks.


Options:
A: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A
B: Arm Label: A. High intensive exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: B. Low-intensive exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active comparator: low intensive exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): A. High intensive exercise | Intervention Type: BEHAVIORAL; Name: Active comparator: low intensive exercise; Assigned to Arm(s): B. Low-intensive exercise
C: Arm Label: Dance Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dance | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: Other: Control Group | Intervention Type: BEHAVIORAL; Name: Dance; Assigned to Arm(s): Dance Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
D: Arm Label: Physcial exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physcial activity | Arm Label: Relaxation exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physcial activity | Intervention Type: BEHAVIORAL; Name: Physcial activity; Assigned to Arm(s): Physcial exercise, Relaxation exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hydroxyethyl Starch 130/0.4 Compared With Balanced Crystalloid Solution on Mortality and Kidney Failure in Patients With Severe Sepsis
Brief Summary: * By tradition hydroxyethyl starch (HES) is used to obtain fast circulatory stabilisation in critically ill.
* High molecular weight HES may, however, cause acute kidney failure in patients with severe sepsis.
* Now the low molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive care units (ICU) and 1st choice fluid for patients with severe sepsis.
* HES 130/0.4 is largely unstudied in ICU patients.
* This investigator-initiated Scandinavian multicentre trial will be conducted to assess the effects of HES 130/0.4 on mortality and endstage kidney failure in patients with severe sepsis.
* The trial will provide important data to all clinicians who resuscitate septic patients.


Options:
A: Arm Label: Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:moderate protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:severe protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Alternative therapy:moderate protein C deficiency, Alternative therapy:severe protein C deficiency, Standard therapy
B: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
D: Arm Label: Drotrecogin alfa (activated); Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hydroxyethyl Starch 130/0.4 Compared With Balanced Crystalloid Solution on Mortality and Kidney Failure in Patients With Severe Sepsis
Brief Summary: * By tradition hydroxyethyl starch (HES) is used to obtain fast circulatory stabilisation in critically ill.
* High molecular weight HES may, however, cause acute kidney failure in patients with severe sepsis.
* Now the low molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive care units (ICU) and 1st choice fluid for patients with severe sepsis.
* HES 130/0.4 is largely unstudied in ICU patients.
* This investigator-initiated Scandinavian multicentre trial will be conducted to assess the effects of HES 130/0.4 on mortality and endstage kidney failure in patients with severe sepsis.
* The trial will provide important data to all clinicians who resuscitate septic patients.


Options:
A: Arm Label: Albumin plus midodrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: albumin, Drug: Midodrine | Arm Label: salin solution plus pills; Type: PLACEBO_COMPARATOR; Interventions: Drug: albumin, Drug: Placebo | Intervention Type: DRUG; Name: albumin; Assigned to Arm(s): Albumin plus midodrine, salin solution plus pills | Intervention Type: DRUG; Name: Midodrine; Assigned to Arm(s): Albumin plus midodrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): salin solution plus pills
B: Intervention Type: DRUG; Name: albumin 4 gr/L ascites removed; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: albumin 8 gr/L ascites removed; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Human Albumin | Intervention Type: DRUG; Name: Human Albumin; Assigned to Arm(s): 2
D: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hydroxyethyl Starch 130/0.4 Compared With Balanced Crystalloid Solution on Mortality and Kidney Failure in Patients With Severe Sepsis
Brief Summary: * By tradition hydroxyethyl starch (HES) is used to obtain fast circulatory stabilisation in critically ill.
* High molecular weight HES may, however, cause acute kidney failure in patients with severe sepsis.
* Now the low molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive care units (ICU) and 1st choice fluid for patients with severe sepsis.
* HES 130/0.4 is largely unstudied in ICU patients.
* This investigator-initiated Scandinavian multicentre trial will be conducted to assess the effects of HES 130/0.4 on mortality and endstage kidney failure in patients with severe sepsis.
* The trial will provide important data to all clinicians who resuscitate septic patients.


Options:
A: Arm Label: 1 Normal Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal Saline | Arm Label: 2 - hypertonic saline mixed with dextran; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline mixed with dextran | Intervention Type: DRUG; Name: hypertonic saline mixed with dextran; Assigned to Arm(s): 2 - hypertonic saline mixed with dextran | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 1 Normal Saline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline (HS) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% normal saline | Intervention Type: DRUG; Name: 7.5% hypertonic saline/6% Dextran-70 (HSD); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 7.5% hypertonic saline (HS); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: 0.9% normal saline; Assigned to Arm(s): 3
C: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
D: Arm Label: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Voluven) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Saline) | Intervention Type: DRUG; Name: Resuscitation (Voluven); Assigned to Arm(s): Voluven | Intervention Type: DRUG; Name: Resuscitation (Saline); Assigned to Arm(s): Saline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hydroxyethyl Starch 130/0.4 Compared With Balanced Crystalloid Solution on Mortality and Kidney Failure in Patients With Severe Sepsis
Brief Summary: * By tradition hydroxyethyl starch (HES) is used to obtain fast circulatory stabilisation in critically ill.
* High molecular weight HES may, however, cause acute kidney failure in patients with severe sepsis.
* Now the low molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive care units (ICU) and 1st choice fluid for patients with severe sepsis.
* HES 130/0.4 is largely unstudied in ICU patients.
* This investigator-initiated Scandinavian multicentre trial will be conducted to assess the effects of HES 130/0.4 on mortality and endstage kidney failure in patients with severe sepsis.
* The trial will provide important data to all clinicians who resuscitate septic patients.


Options:
A: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
B: Arm Label: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Voluven) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Saline) | Intervention Type: DRUG; Name: Resuscitation (Voluven); Assigned to Arm(s): Voluven | Intervention Type: DRUG; Name: Resuscitation (Saline); Assigned to Arm(s): Saline
C: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A
D: Arm Label: Hydroxy-ethyl starch; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxy-ethyl starch (130/0.4) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: 6% Hydroxy-ethyl starch (130/0.4); Assigned to Arm(s): Hydroxy-ethyl starch | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Orthokeratology for Myopic Control in Chinese Children - a Randomized Clinical Trial
Brief Summary: The primary aim of this study is to evaluate and compare the eyeball elongation in children wearing orthokeratology lenses and single-vision spectacles.


Options:
A: Arm Label: orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: orthokeratology lenses | Arm Label: single-vision spectacle lenses; Type: OTHER; Interventions: Device: single-vision spectacle lenses | Intervention Type: DEVICE; Name: orthokeratology lenses; Assigned to Arm(s): orthokeratology lenses | Intervention Type: DEVICE; Name: single-vision spectacle lenses; Assigned to Arm(s): single-vision spectacle lenses
B: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
C: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)
D: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Orthokeratology for Myopic Control in Chinese Children - a Randomized Clinical Trial
Brief Summary: The primary aim of this study is to evaluate and compare the eyeball elongation in children wearing orthokeratology lenses and single-vision spectacles.


Options:
A: Arm Label: Bifocal Contact Lenses; Type: EXPERIMENTAL; Interventions: Device: Bifocal Contact Lenses | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo Control | Intervention Type: DEVICE; Name: Bifocal Contact Lenses; Assigned to Arm(s): Bifocal Contact Lenses | Intervention Type: DEVICE; Name: Placebo Control; Assigned to Arm(s): Control
B: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
C: Arm Label: orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: orthokeratology lenses | Arm Label: single-vision spectacle lenses; Type: OTHER; Interventions: Device: single-vision spectacle lenses | Intervention Type: DEVICE; Name: orthokeratology lenses; Assigned to Arm(s): orthokeratology lenses | Intervention Type: DEVICE; Name: single-vision spectacle lenses; Assigned to Arm(s): single-vision spectacle lenses
D: Arm Label: omafilcon A; Type: EXPERIMENTAL; Interventions: Device: omafilcon A | Arm Label: Spectacle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: omafilcon A; Assigned to Arm(s): omafilcon A | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The European Quality of Care Pathways Study: The Impact of a Care Pathway for Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) : an International Cluster Randomized Controlled Trial." (Www.E-P-A.Org)
Brief Summary: Care pathways, a complex intervention to (re)organise, standardize and evaluate care processes, are used worldwide and in different kinds of settings. Although their international use, the impact is unclear. The European Quality of Care Pathways Study is the first international cluster Randomized Controlled Trial on the effect of care pathways for COPD patients.

The hypothesis is that teams who work with care pathways for COPD patients deliver care that is more compliant to evidence based key interventions, have better patient outcomes and higher scores on team indicators than teams who do not work with care pathways.


Options:
A: Arm Label: Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health Coaching | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health Coaching; Assigned to Arm(s): Health Coaching
B: Arm Label: NMS; Type: EXPERIMENTAL; Interventions: Other: New Medicine Service | Arm Label: Current Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New Medicine Service; Assigned to Arm(s): NMS
C: Arm Label: Activity Monitoring - Smartphone; Type: N/A; Interventions: N/A | Arm Label: Activity Monitoring - Wearable; Type: N/A; Interventions: N/A
D: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: COPD evidence based care pathway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPD evidence based care pathway; Assigned to Arm(s): Pathway

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The European Quality of Care Pathways Study: The Impact of a Care Pathway for Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) : an International Cluster Randomized Controlled Trial." (Www.E-P-A.Org)
Brief Summary: Care pathways, a complex intervention to (re)organise, standardize and evaluate care processes, are used worldwide and in different kinds of settings. Although their international use, the impact is unclear. The European Quality of Care Pathways Study is the first international cluster Randomized Controlled Trial on the effect of care pathways for COPD patients.

The hypothesis is that teams who work with care pathways for COPD patients deliver care that is more compliant to evidence based key interventions, have better patient outcomes and higher scores on team indicators than teams who do not work with care pathways.


Options:
A: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management
B: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: COPD evidence based care pathway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPD evidence based care pathway; Assigned to Arm(s): Pathway
C: Arm Label: spirometry, patient activation tool; Type: EXPERIMENTAL; Interventions: Other: provider support tools plus spirometer | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: provider support tools plus spirometer; Assigned to Arm(s): spirometry, patient activation tool
D: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)

Answer: B